Literature DB >> 32632880

The Landmark Series: Neuroendocrine Tumor Liver Metastases.

Alexandra Gangi1, James R Howe2.   

Abstract

BACKGROUND: Neuroendocrine tumors are becoming increasingly prevalent, with many patients presenting with or developing metastatic disease to the liver.
METHODS: In this landmark series paper, we highlight the critical studies that have defined the surgical management of neuroendocrine tumor liver metastases, as well as several randomized control trials which have investigated strategies for systemic control of metastatic disease.
RESULTS: Liver-directed surgical approaches and locally ablative procedures are recommended for patients with limited, resectable, and in some cases, nonresectable tumor burden. Angiographic liver-directed techniques, such as transarterial embolization, chemoembolization, and radioembolization, offer another approach for management in patients with liver-predominant disease. Peptide receptor radionuclide therapy is a promising therapy for patients with hepatic and/or extrahepatic metastases. Various systemic medical therapies are also available as adjunct or definitive therapy for patients with metastatic disease.
CONCLUSIONS: This article reviews current data regarding management of neuroendocrine liver metastases and highlights areas for future study.

Entities:  

Keywords:  Liver debulking; Liver metastases; Neuroendocrine; PRRT

Mesh:

Substances:

Year:  2020        PMID: 32632880      PMCID: PMC7415723          DOI: 10.1245/s10434-020-08787-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  55 in total

1.  ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.

Authors:  Marianne Pavel; Eric Baudin; Anne Couvelard; Eric Krenning; Kjell Öberg; Thomas Steinmüller; Martin Anlauf; Bertram Wiedenmann; Ramon Salazar
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

2.  Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury.

Authors:  Nikhil Bhagat; Diane K Reyes; Mingde Lin; Ihab Kamel; Timothy M Pawlik; Constantine Frangakis; J F Geschwind
Journal:  Cardiovasc Intervent Radiol       Date:  2012-06-22       Impact factor: 2.740

Review 3.  Liver Metastases.

Authors:  J H Foster; J Lundy
Journal:  Curr Probl Surg       Date:  1981-03       Impact factor: 1.909

4.  Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis.

Authors:  Skye C Mayo; Mechteld C de Jong; Carlo Pulitano; Brian M Clary; Srinevas K Reddy; T Clark Gamblin; Scott A Celinksi; David A Kooby; Charles A Staley; Jayme B Stokes; Carrie K Chu; Alessandro Ferrero; Richard D Schulick; Michael A Choti; Giles Mentha; Jennifer Strub; Todd W Bauer; Reid B Adams; Luca Aldrighetti; Lorenzo Capussotti; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2010-06-29       Impact factor: 5.344

5.  Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors.

Authors:  M Cives; M Ghayouri; B Morse; M Brelsford; M Black; A Rizzo; A Meeker; J Strosberg
Journal:  Endocr Relat Cancer       Date:  2016-09       Impact factor: 5.678

6.  Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database.

Authors:  Roberto Gedaly; Michael F Daily; Daniel Davenport; Patrick P McHugh; Alvaro Koch; Paul Angulo; Jonathan C Hundley
Journal:  Arch Surg       Date:  2011-08

7.  Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients.

Authors:  Xiang Da Dong; Brian I Carr
Journal:  Med Oncol       Date:  2010-11-24       Impact factor: 3.064

8.  Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.

Authors:  Juan M Sarmiento; Glenroy Heywood; Joseph Rubin; Duane M Ilstrup; David M Nagorney; Florencia G Que
Journal:  J Am Coll Surg       Date:  2003-07       Impact factor: 6.113

Review 9.  Liver transplantation for neuroendocrine tumour liver metastases.

Authors:  Sheung Tat Fan; Yves Patrice Le Treut; Vincenzo Mazzaferro; Andrew K Burroughs; Michael Olausson; Stefan Breitenstein; Andrea Frilling
Journal:  HPB (Oxford)       Date:  2014-07-03       Impact factor: 3.647

10.  Hepatic resection for metastatic neuroendocrine carcinomas.

Authors:  F G Que; D M Nagorney; K P Batts; L J Linz; L K Kvols
Journal:  Am J Surg       Date:  1995-01       Impact factor: 2.565

View more
  4 in total

1.  Neuroendocrine hepatic metastatic disease: the surgeon's perspective.

Authors:  Seth J Concors; Jessica E Maxwell
Journal:  Abdom Radiol (NY)       Date:  2022-04-27

Review 2.  Diagnosis and Surgical Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: A Literature Review.

Authors:  Shuzo Kohno
Journal:  Cancer Diagn Progn       Date:  2022-03-03

Review 3.  The Landmark Series: Management of Small Bowel Neuroendocrine Tumors.

Authors:  Catherine G Tran; Scott K Sherman; James R Howe
Journal:  Ann Surg Oncol       Date:  2021-01-15       Impact factor: 5.344

4.  Feasibility and Early Clinical Experience of Online Adaptive MR-Guided Radiotherapy of Liver Tumors.

Authors:  Paul Rogowski; Rieke von Bestenbostel; Franziska Walter; Katrin Straub; Lukas Nierer; Christopher Kurz; Guillaume Landry; Michael Reiner; Christoph Josef Auernhammer; Claus Belka; Maximilian Niyazi; Stefanie Corradini
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.